NCT01947855View on ClinicalTrials.gov

Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

Placebo tablet matching Empagliflozin low dose

DRUG

Empagliflozin

Empagliflozin low dose

DRUG

Placebo

Placebo tablet matching Empagliflozin high dose

DRUG

Placebo

Placebo tablet matching Empagliflozin low dose

DRUG

Empagliflozin

Empagliflozin high dose tablet once daily

DRUG

Placebo

Placebo tablet matching Empagliflozin high dose

Trial Locations (2)

Unknown

1245.35.002 Boehringer Ingelheim Investigational Site, Shinjyuku-ku, Tokyo

1245.35.001 Boehringer Ingelheim Investigational Site, Suita-shi, Osaka

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT01947855 - Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter